Photo of David C. Fisher,  MD

David C. Fisher, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3039
Fax: (617) 632-4422


david_c_fisher@dfci.harvard.edu

David C. Fisher, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Instructor, Adult Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our primary focus is the comprehensive treatment of patients with non-Hodgkin’s lymphoma, Hodgkin’s disease, and chronic lymphocytic leukemia (CLL). This clinical work includes the expert use of chemotherapy, radiation therapy, and stem cell transplant procedures. Our practice, located at the Lymphoma Clinic at Dana-Farber, is a combined clinic that includes radiation oncologists who specialize in lymphoma. Dr. Fisher attends on the Lymphoma and Bone Marrow Transplant services at the Brigham and Women’s Hospital, and is the oncologist providing specialty care in the Cutaneous Lymphoma Clinic in conjunction with the Department of Dermatology. This large volume practice allows us to provide expertise in all types of lymphoma.



Our research interests are in the use of novel drug combinations to improve therapy for different subtypes of lymphoma, in particular, the evolving field of immunotherapies and radioimmunotherapies for this population of patients. We are also conducting clinical trials evaluating the use of high-dose chemotherapy with autologous or allogeneic bone marrow transplant. The latter includes the use of ablative and non-myeloablative preparative regimens with both related and unrelated donors. The focus of these studies is the optimal use of each of these strategies for the many types of non-Hodgkin’s lymphoma and Hodgkin’s disease. This focus allows for continuity of care for patients with lymphoma who require expert management of these modalities.

Publications

Powered by Harvard Catalyst
  • Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2015. PubMed
  • Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen E. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant 2015. PubMed
  • Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 2015. PubMed
  • Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma 2015. PubMed
  • Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 2015; 27:327-41. PubMed
  • Chen MH, Blackington LH, Zhou J, Chu TF, Gauvreau K, Marcus KJ, Fisher DC, Diller LR, Ng AK. Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation. Leuk Lymphoma 2014. PubMed
  • Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol 2014. PubMed
  • Mane M, O'Neill AC, Tirumani SH, Shi M, Shinagare AB, Fisher DC. Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances. Clin Imaging 2014. PubMed
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. British Journal of Haematology 2013; 163:123-6. PubMed
  • Nambudiri VE, Mutyambizi K, Walls AC, Fisher DC, Bleday R, Saavedra AP. Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir. JAMA Dermatol 2013; 149:1068-70. PubMed
  • Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma 2013. PubMed
  • Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 2013; 19:3755-63. PubMed
  • Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol 2013. PubMed
  • Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica 2013. PubMed
  • Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013. PubMed
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. British Journal of Haematology 2013; 160:608-17. PubMed
  • Velez NF, Ishizawar RC, Dellaripa PF, Saavedra AP, Laga AC, Murphy GF, Fisher DC, Kupper TS, Vleugels RA. Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol 2012; 30:e233-6. PubMed
  • Parithivel K, Ramaiya N, Jagannathan JP, O'Regan K, Krajewski K, Fisher D, Choueiri TK, Jacobsen E. Everolimus- and temsirolimus-associated enteritis: report of three cases. J Clin Oncol 2011. PubMed
  • Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients Leuk Lymphoma 2010; 51:789-96. PubMed
  • Canellos GP, Abramson JS, Fisher DC, Lacasce AS. Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy. J Clin Oncol 2010; 28:1611-5. PubMed
  • Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology 2009; 146:282-91. PubMed
  • Brown JR,Friedberg JW,Feng Y,Scofield S,Phillips K,Dal Cin P,Joyce R,Takvorian RW,Fisher DC,Fisher RI,Liesveld J,Marquis D,Neuberg D,Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology 2009; 145:741-8. PubMed
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767-74. PubMed
  • Luthy SK,Ng AK,Silver B,Degnan KO,Fisher DC,Freedman AS,Mauch PM. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol 2008; 19:2043-7. PubMed
  • Brown JR,Neuberg D,Phillips K,Reynolds H,Silverstein J,Clark JC,Ash M,Thompson C,Fisher DC,Jacobsen E,LaCasce AS,Freedman AS. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. British Journal of Haematology 2008; 143:361-8. PubMed
  • Ng AK, Li S, Neuberg D, Chi R, Fisher DC, Silver B, Mauch PM. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol 2008; 19:1754-8. PubMed
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma 2008; 49:902-9. PubMed
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046-51. PubMed
  • Drappatz J, Akar S, Fisher DC, Samuels MA, Kesari S. Imaging of Bing-Neel syndrome. Neurology 2008; 70:1364. PubMed
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418-25. PubMed
  • Sato-Jin K, Nishimura EK, Akasaka E, Huber W, Nakano H, Miller A, Du J, Wu M, Hanada K, Sawamura D, Fisher DE, Imokawa G. Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB J 2007; 22:1155-68. PubMed
  • Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G. Meeting Report: Fourth International Congress of the Society for Melanoma Research. Pigment Cell Melanoma Res 2008; 21:15-26. PubMed
  • Kawakami A, Sakane F, Imai S, Yasuda S, Kai M, Kanoh H, Jin HY, Hirosaki K, Yamashita T, Fisher DE, Jimbow K. Rab7 regulates maturation of melanosomal matrix protein gp100/Pmel17/Silv. J Invest Dermatol 2007; 128:143-50. PubMed
  • Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:1151-7. PubMed
  • Widlund HR, Fisher DE. Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis. Pigment Cell Res 2007; 20:339-40. PubMed
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13:1057-65. PubMed
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13:838-43. PubMed
  • Ng AK, Li S, Neuberg D, Fisher DC, McMillan C, Silver B, Marcus KC, Stevenson MA, Mauch PM. Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease. Ann Oncol 2006; 17:1693-7. PubMed
  • Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006; 12:1056-64. PubMed
Hide